MapLight Therapeutics, Inc.
NASDAQ:MPLTBiotechnology
+$0.39 today
- Market cap
- $283.41M
- Beta
- 2.65
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$4.41
Volume 0.42M
Average 0.73M
MPLT Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
MapLight Therapeutics, Inc.NASDAQ: MPLT
Short-term Investments · Q1 FY2026 · quarter ended Mar 2026
Short-term investments rises 504.2% from a year ago
Short-term investments stood at $254.41M at the end of Q1 FY2026, up 504.2% from a year earlier and down 1.5% from the prior quarter.
Context
- Short-term investments amounted to 60.7% of total assets at the end of Q1 FY2026, up 23.0 pp from a year earlier.
- Short-term investments increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether short-term investments keeps rising in the next quarterly balance sheet after a +504.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 258.37M USD
- Year-over-year change
- +266.3%
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 258.37M | +266.3% |
| FY2024 | 2024-12-31 | 70.54M | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Short-term Investments vs competitors
How MPLT compares with its peers on the latest reported figures
- MPLT's Mar 2026 short-term investments of $254.41M is the 4th highest of the 11 companies compared; the peer median is $34.82M.
- Its year-over-year change of +504.2% is the highest of 7, against a peer median of +14.1%.
- Short-term investments amounts to 60.7% of total assets for MPLT, versus a peer median of 10.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $50.62B | — | — | 53.2% | |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $805.7M | +326.0% | — | 75.0% |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $398.73M | +75.1% | — | 80.1% |
| Mar 2026 | $254.41M | +504.2% | — | 60.7% | |
| Mar 2026 | $61.46M | +181.1% | -12.4% | 27.2% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $44.96M | — | — | 11.4% |
| Mar 2026 | $24.67M | -46.8% | — | 9.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | -100.0% | +94.9% | 0.0% | |
| Dec 2025 | $0 | — | — | 0.0% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $0 | -100.0% | — | 0.0% |
| Peer median (excluding MPLT) | $34.82M | +14.1% | +41.2% | 10.2% | |
Competitors are the stored peer set for MPLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MapLight Therapeutics, Inc.
NASDAQ:MPLT
Intrinsic Alpha fair value
Locked
Current Price
$6.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.